Outcome measurement of refractory breathlessness: Endpoints and important differences

Current Opinion in Supportive and Palliative Care

Volumn 9, Issue 3, 2015, Pages 238-243

  Ekstrom, Magnus ^a,b   Currow, David C ^a   Johnson, Miriam J ^c  

^a FLINDERS UNIVERSITY   (Australia)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Breathlessness; Dyspnea; Minimal clinically important difference; Outcome measure

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; HUMAN; INJURY SCALE; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PSYCHOLOGY; QUALITY OF LIFE; SELF REPORT; TREATMENT OUTCOME;

DYSPNEA; HUMANS; PALLIATIVE CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SELF REPORT; TRAUMA SEVERITY INDICES; TREATMENT OUTCOME;

EID: 84942938040     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000147     Document Type: Review

References (40)

1. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185:435-452.
2. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327:523-528.
3. Moens K, Higginson IJ, Harding R. Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight noncancer conditions? A systematic review. J Pain Symptom Manage 2014; 48:660-677.
4. Ekstrom MP, Abernethy AP, Currow DC. The management of chronic breath-lessness in patients with advanced and terminal illness. BMJ 2015; 349:g7617.
5. From the global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014. Available from: Http://www.Goldcopd.Org/.
6. Johnson MJ, Currow DC, Booth S. Prevalence and assessment of breath-lessness in the clinical setting. Expert Rev Respir Med 2014; 8:151-161.
7. Evans CJ, Benalia H, Preston NJ, et al. The selection and use of outcome measures in palliative and end-of-life care research: the MORECare International Consensus Workshop. J Pain Symptom Manage 2013; 46:925-937.
8. Johnson MJ, Oxberry SG, Cleland JG, Clark AL. Measurement of breath-lessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review. Eur J Heart Fail 2010; 12:137-147.
9. Dorman S, Jolley C, Abernethy A, et al. Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. Palliat Med 2009; 23:213-227.
10. Bausewein C, Booth S, Higginson IJ. Measurement of dyspnoea in the clinical rather than the research setting. Curr Opin Support Palliat Care 2008; 2:95-99.
11. Tanaka K, Akechi T, Okuyama T, et al. Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Br J Cancer 2000; 82:800-805.
12. Jones P, Beeh K, Chapman K, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189:250-255.
13. Leidy N, Sexton C, Jones P, et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax 2014; 69:424-430.
14. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415.
15. Wilcox TK, Chen WH, Howard KA, et al. Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease. Health Qual Life Outcomes 2013; 11:196.
16. Yorke J, Swigris J, Russell AM, et al. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 2011; 139:159-164.
17. Meek PM, Banzett R, Parshall MB, et al. Reliability and validity of the multidimensional dyspnea profile. Chest 2012; 141:1546-1553.
18. Parshall MB, Meek PM, Sklar D, et al. Test-retest reliability of multidimensional dyspnea profile recall ratings in the emergency department: a prospective, longitudinal study. BMC Emerg Med 2012; 12:6.
19. Banzett RB, O'Donnell CR, Guilfoyle TE, et al. Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research. Eur Resp J 2015; 45:1681-1691.
20. Simon ST, Altfelder N, Alt-Epping B, et al. Is breathlessness what the professional says it is? Analysis of patient and professionals' assessments from a German nationwide register. Support Care Cancer 2014; 22:1825-1832.
21. Leidy N, Murray L, Jones P, Sethi S. Performance of the Exacerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11:316-325.
22. Leidy N, Murray L, Monz B, et al. Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res 2014; 15:124.
23. Watkins ML, Wilcox TK, Tabberer M, et al. Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open 2013; 3:e003048.
24. Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010; 65:21-26.
25. Yorke J, Russell AM, Swigris J, et al. Assessment of dyspnea in asthma: validation of The Dyspnea-12. J Asthma 2011; 48:602-608.
26. Higginson I, Priest P, McCarthy M. Are bereaved family members a valid proxy for a patient's assessment of dying? Soc Sci Med 1994; 38:553-557.
27. Quinn C, Dunbar SB, Higgins M. Heart failure symptom assessment and management: can caregivers serve as proxy? J Cardiovasc Nurs 2010; 25:142-148.
28. Hayes AW, Philip J, Spruyt OW. Patient reporting and doctor recognition of dyspnoea in a comprehensive cancer centre. Intern Med J 2006; 36:381-384.
29. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77:371-383.
30. Hui D, Zhukovsky DS, Bruera E. Which treatment is better? Ascertaining patient preferences with crossover randomized controlled trials. J Pain Symptom Manage 2015; 49:625-631.
31. Johnson MJ, Bland JM, Oxberry SG, et al. Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manage 2013; 46:957-963.
32. Johnson MJ, Bland JM, Oxberry SG, et al. Measuring improvement in dys-pnoea: should absolute or relative values be used? Eur Respir J 2014; 44:1700-1703.
33. Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure- A pilot study. Eur J Heart Fail 2002; 4:753-756.
34. Oxberry SG, Torgerson DJ, Bland JM, et al. Short-term opioids for breath-lessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail 2011; 13:1006-1012.
35. Currow DC, McDonald C, Oaten S, et al. Once-Daily Opioids for Chronic Dyspnea: A Dose Increment and Pharmacovigilance Study. J Pain Sympt Manag 2011; 42:388-399.
36. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
37. Ander DS, Aisiku IP, Ratcliff JJ, et al. Measuring the dyspnea of decom-pensated heart failure with a visual analog scale: how much improvement is meaningful? Congest Heart Fail 2004; 10:188-191.
38. Karras DJ, Sammon ME, Terregino CA, et al. Clinically meaningful changes in quantitative measures of asthma severity. Acad Emerg Med 2000; 7:327-334.
39. Booth S. Improving research methodology in breathlessness: a meeting convened by the MRC clinical trials unit and the Cicely Saunders Foundation. Palliat Med 2006; 20:219-220.
40. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005; 2:105-110.